About: Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates
Creator	Liu, Gang Liu, Jiangning Qin, Chuan Xu, Yanfeng Zhang, Lianfeng Li, Li Xie, Jing Li, Taisheng Kuwahara, Kazuhiko Sakaguchi, Nobuo Zhu, Hua Wang, Qidi Liu, Zijie Morioka, Hiroshi
topic	covid:8d8bd0ddbc0ec808e96e01e0f77227b73e3325fc#this
Source	Medline; PMC
abstract	[Image: see text] Severe acute respiratory syndrome (SARS) is caused by a coronavirus (SARS-CoV) and has the potential to threaten global public health and socioeconomic stability. Evidence of antibody-dependent enhancement (ADE) of SARS-CoV infection in vitro and in non-human primates clouds the prospects for a safe vaccine. Using antibodies from SARS patients, we identified and characterized SARS-CoV B-cell peptide epitopes with disparate functions. In rhesus macaques, the spike glycoprotein peptides S(471–503), S(604–625), and S(1164–1191) elicited antibodies that efficiently prevented infection in non-human primates. In contrast, peptide S(597–603) induced antibodies that enhanced infection both in vitro and in non-human primates by using an epitope sequence-dependent (ESD) mechanism. This peptide exhibited a high level of serological reactivity (64%), which resulted from the additive responses of two tandem epitopes (S(597–603) and S(604–625)) and a long-term human B-cell memory response with antisera from convalescent SARS patients. Thus, peptide-based vaccines against SARS-CoV could be engineered to avoid ADE via elimination of the S(597–603) epitope. We provide herein an alternative strategy to prepare a safe and effective vaccine for ADE of viral infection by identifying and eliminating epitope sequence-dependent enhancement of viral infection.
has issue date	2016-04-11(xsd:dateTime)
bibo:doi	10.1021/acsinfecdis.6b00006
bibo:pmid	27627203
has license	bronze-oa
sha1sum (hex)	8d8bd0ddbc0ec808e96e01e0f77227b73e3325fc
schema:url	https://doi.org/10.1021/acsinfecdis.6b00006
resource representing a document's title	Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates
has PubMed Central identifier	PMC7075522
has PubMed identifier	27627203
schema:publication	ACS Infectious Diseases
resource representing a document's body	covid:8d8bd0ddbc0ec808e96e01e0f77227b73e3325fc#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/8d8bd0ddbc0ec808e96e01e0f77227b73e3325fc
is schema:about of	named entity 'antisera' named entity 'infection' named entity 'viral infection' named entity 'ADE' named entity 'mechanism' named entity 'non-human primates' named entity 'peptide' covid:arg/8d8bd0ddbc0ec808e96e01e0f77227b73e3325fc named entity 'serological' named entity 'elimination' named entity 'stability' named entity 'strategy' named entity 'infection' named entity 'ADE' named entity 'antibodies' named entity 'SARS' named entity 'epitope' named entity 'socioeconomic' named entity 'antisera' named entity 'ADE' named entity 'viral infection' named entity 'epitopes' named entity 'non-human primates' named entity 'peptide' named entity 'vaccines' named entity 'antibodies' named entity 'antibody-dependent enhancement' named entity 'ADE' named entity 'vaccines' named entity 'ADE' named entity 'peptides' named entity 'macaques' named entity 'left lung' named entity 'tissue sections' named entity 'mmol' named entity 'haptens' named entity 'long-term' named entity 'murine' named entity 'Tokyo' named entity 'epidemic' named entity 'influenza A virus' named entity 'lung tissue' named entity 'IACUC' named entity 'Immunodominant' named entity 'vaccine' named entity 'HPLC' named entity 'spike protein' named entity 'amino acid residues' named entity 'interstitial pneumonitis' named entity 'San Francisco, CA' named entity 'qRT-PCR' named entity 'triethylsilane' named entity 'nucleocapsid' named entity 'antigenic peptides' named entity 'PBS' named entity 'antisera' named entity 'SARS-CoV' named entity 'vaccine' named entity 'hemorrhage' named entity 'PBS' named entity 'Epitope' named entity 'SARS-CoV' named entity 'ADE' named entity 'rhesus monkeys' named entity 'Ebola' named entity 'complement'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software